High‐dose opioid use and liver transplantation: An underestimated problem?
Shari Rogal, Mary Amanda Dew, Andrea DiMartini – 30 January 2017
The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus
Jin Y. Choi, Jeong I. Yu, Hee C. Park, C. H. David Kwon, Jong M. Kim, Jae‐Won Joh, Gyu‐Seong Choi, Jae B. Park, Sung J. Kim, Seung H. Lee, Won‐Tae Cho, Kyo W. Lee, Byeong‐Gon Na, Dong Kyu Oh, Nuri Lee, Chan W. Cho, Sanghoon Lee, Suk‐Koo Lee – 30 January 2017
AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach, Laura M. Kulik, Richard S. Finn, Claude B. Sirlin, Michael M. Abecassis, Lewis R. Roberts, Andrew X. Zhu, M. Hassan Murad, Jorge A. Marrero – 28 January 2017
Reply
Juan G. Abraldes, Annalisa Berzigotti, on behalf of the ANTICIPATE INVESTIGATORS – 28 January 2017
AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach, Laura M. Kulik, Richard S. Finn, Claude B. Sirlin, Michael M. Abecassis, Lewis R. Roberts, Andrew X. Zhu, M. Hassan Murad, Jorge A. Marrero – 28 January 2017
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
Parambir S. Dulai, Siddharth Singh, Janki Patel, Meera Soni, Larry J. Prokop, Zobair Younossi, Giada Sebastiani, Mattias Ekstedt, Hannes Hagstrom, Patrik Nasr, Per Stal, Vincent Wai‐Sun Wong, Stergios Kechagias, Rolf Hultcrantz, Rohit Loomba – 28 January 2017 – Liver fibrosis is the most important predictor of mortality in nonalcoholic fatty liver disease (NAFLD). Quantitative risk of mortality by fibrosis stage has not been systematically evaluated. We aimed to quantify the fibrosis stage–specific risk of all‐cause and liver‐related mortality in NAFLD.
AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach, Laura M. Kulik, Richard S. Finn, Claude B. Sirlin, Michael M. Abecassis, Lewis R. Roberts, Andrew X. Zhu, M. Hassan Murad, Jorge A. Marrero – 28 January 2017
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
Parambir S. Dulai, Siddharth Singh, Janki Patel, Meera Soni, Larry J. Prokop, Zobair Younossi, Giada Sebastiani, Mattias Ekstedt, Hannes Hagstrom, Patrik Nasr, Per Stal, Vincent Wai‐Sun Wong, Stergios Kechagias, Rolf Hultcrantz, Rohit Loomba – 28 January 2017 – Liver fibrosis is the most important predictor of mortality in nonalcoholic fatty liver disease (NAFLD). Quantitative risk of mortality by fibrosis stage has not been systematically evaluated. We aimed to quantify the fibrosis stage–specific risk of all‐cause and liver‐related mortality in NAFLD.
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment
Fred Poordad, Franco Felizarta, Armen Asatryan, Mark S. Sulkowski, Robert W. Reindollar, Charles S. Landis, Stuart C. Gordon, Steven L. Flamm, Michael W. Fried, David E. Bernstein, Chih‐Wei Lin, Ran Liu, Sandra S. Lovell, Teresa I. Ng, Jens Kort, Federico J. Mensa – 27 January 2017 – Although direct‐acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstrated high rates of sustained virologic response, virologic failure may still occur, potentially leading to the emergence of viral resistance, which can decrease the effectiveness of subsequent treatment.
Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta‐analysis
Sonali Paul, Aaron Dickstein, Akriti Saxena, Norma Terrin, Kathleen Viveiros, Ethan M. Balk, John B. Wong – 27 January 2017 – Patients with resolved hepatitis B virus (HBV) infection who are treated for hematological malignancies remain at risk for HBV reactivation.